Tuesday, October 07, 2014

Investigational Antiviral Drug approved for use on US Ebola patient

The FDA approved the use of an investigational drug, CMX001 (brincidofovir),  to attempt to treat Ebola Virus Disease in the sole US case so far.  The drug has been in clinical trials for Cytomegalovirus (CMV) infection, a common complication in bone-marrow transplants and other immunosupressed populations.  The drug has also been used for Adenovirus infections in pediatric cancer patients.  Based on its activity against poxviruses it was selected for investigation as a possible treatment for Smallpox (Variola) infection for bioterrorism defense.

Brincidofovir is an orally active prodrug of cidofovir (Vistide), an injectable antiviral drug used to treat CMV retinitis in AIDS patients.  Brincidofovir is converted to the active drug in the body and its lipid conjugation allows lower plasma levels (less toxicity) and higher levels inside cells, where it can act on the virus.

Link to Publication of CMX001 efficacy in Herpes Virus Infections -Note: CMV is in the Herpes Virus family.  Paper give some background on the mechanism of action in Brincidofovir.

Chimerix Press Release

No comments: